| Rose M Ryba, OTR/L | |
|
11380 S 60th Ct, Papillion, NE 68133-3214 | |
| (402) 885-7000 | |
| (402) 682-4256 |
| Full Name | Rose M Ryba |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Gerontology |
| Location | 11380 S 60th Ct, Papillion, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386975779 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XG0600X | Occupational Therapist - Gerontology | 1313 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rose M Ryba, OTR/L 11380 S 60th Ct, Papillion, NE 68133-3214 Ph: (402) 885-7000 | Rose M Ryba, OTR/L 11380 S 60th Ct, Papillion, NE 68133-3214 Ph: (402) 885-7000 |
News Archive
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.
Higher cost of care and worse patient outcomes are associated with incontinence and incontinence-associated dermatitis (IAD) in acute care settings, according to analysis published in the Journal of Wound, Ostomy, and Continence Nursing, the official journal of the Wound, Ostomy, and Continence Nurses Society.
A team from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University has made a major breakthrough by unraveling the inner workings of melatonin, also known as the "sleep hormone."
Blue Mountain Quality Resources, Inc. (State College, PA) announced today that Wake Forest Institute for Regenerative Medicine has chosen Blue Mountain Regulatory Asset Manager to manage and document activities for its clinical manufacturing center.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
› Verified 6 days ago
Krista Wear, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 420 S Washington St, Papillion, NE 68046 Phone: 402-537-6222 | |
Leanna Marie Fronckowiak, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10601 S 72nd St, Papillion, NE 68046 Phone: 402-932-2782 | |
Lisa S Scheet, MA, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1203 Rogers Dr, Papillion, NE 68046 Phone: 402-331-2593 | |
Ms. Kristin Lea Fricke, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 420 S Washington St, Papillion, NE 68046 Phone: 402-537-6222 | |
Jessica Marie Ackermann, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10791 S 72nd St, 103, Papillion, NE 68046 Phone: 402-932-2782 Fax: 402-932-2705 | |
Mrs. Kimberly Kay Miller, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 610 S Polk St, Papillion, NE 68046 Phone: 402-339-7700 | |
Madison K Gallagher, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10601 S 72nd St, Papillion, NE 68046 Phone: 402-932-2782 |